425 related articles for article (PubMed ID: 17390075)
1. Distinct responses of two hepatocellular carcinoma cell lines of a similar origin to immunotherapies targeting regulatory or effector T cells.
Nagayama Y; Hase W; Motoyoshi Y; Saitoh O; Sogawa R; Nakao K
Oncol Rep; 2007 May; 17(5):1269-73. PubMed ID: 17390075
[TBL] [Abstract][Full Text] [Related]
2. GITR ligand-costimulation activates effector and regulatory functions of CD4+ T cells.
Igarashi H; Cao Y; Iwai H; Piao J; Kamimura Y; Hashiguchi M; Amagasa T; Azuma M
Biochem Biophys Res Commun; 2008 May; 369(4):1134-8. PubMed ID: 18346459
[TBL] [Abstract][Full Text] [Related]
3. Targeting acute allograft rejection by immunotherapy with ex vivo-expanded natural CD4+ CD25+ regulatory T cells.
Xia G; He J; Zhang Z; Leventhal JR
Transplantation; 2006 Dec; 82(12):1749-55. PubMed ID: 17198271
[TBL] [Abstract][Full Text] [Related]
4. In vivo expansion of CD4+Foxp3+ regulatory T cells mediated by GITR molecules.
Nishioka T; Nishida E; Iida R; Morita A; Shimizu J
Immunol Lett; 2008 Dec; 121(2):97-104. PubMed ID: 18930767
[TBL] [Abstract][Full Text] [Related]
5. Depletion of CD4+CD25+ regulatory T cells enhances interleukin-2-induced antitumor immunity in a mouse model of colon adenocarcinoma.
Imai H; Saio M; Nonaka K; Suwa T; Umemura N; Ouyang GF; Nakagawa J; Tomita H; Osada S; Sugiyama Y; Adachi Y; Takami T
Cancer Sci; 2007 Mar; 98(3):416-23. PubMed ID: 17270031
[TBL] [Abstract][Full Text] [Related]
6. Function of CD4+,CD25+ Treg cells in MRL/lpr mice is compromised by intrinsic defects in antigen-presenting cells and effector T cells.
Parietti V; Monneaux F; Décossas M; Muller S
Arthritis Rheum; 2008 Jun; 58(6):1751-61. PubMed ID: 18512811
[TBL] [Abstract][Full Text] [Related]
7. Reciprocal CD4+ T-cell balance of effector CD62Llow CD4+ and CD62LhighCD25+ CD4+ regulatory T cells in small cell lung cancer reflects disease stage.
Koyama K; Kagamu H; Miura S; Hiura T; Miyabayashi T; Itoh R; Kuriyama H; Tanaka H; Tanaka J; Yoshizawa H; Nakata K; Gejyo F
Clin Cancer Res; 2008 Nov; 14(21):6770-9. PubMed ID: 18980970
[TBL] [Abstract][Full Text] [Related]
8. Multiple antitumor mechanisms downstream of prophylactic regulatory T-cell depletion.
Teng MW; Swann JB; von Scheidt B; Sharkey J; Zerafa N; McLaughlin N; Yamaguchi T; Sakaguchi S; Darcy PK; Smyth MJ
Cancer Res; 2010 Apr; 70(7):2665-74. PubMed ID: 20332236
[TBL] [Abstract][Full Text] [Related]
9. Regulatory T cell-resistant CD8+ T cells induced by glucocorticoid-induced tumor necrosis factor receptor signaling.
Nishikawa H; Kato T; Hirayama M; Orito Y; Sato E; Harada N; Gnjatic S; Old LJ; Shiku H
Cancer Res; 2008 Jul; 68(14):5948-54. PubMed ID: 18632650
[TBL] [Abstract][Full Text] [Related]
10. Systemic anti-CD25 monoclonal antibody administration safely enhances immunity in murine glioma without eliminating regulatory T cells.
Fecci PE; Sweeney AE; Grossi PM; Nair SK; Learn CA; Mitchell DA; Cui X; Cummings TJ; Bigner DD; Gilboa E; Sampson JH
Clin Cancer Res; 2006 Jul; 12(14 Pt 1):4294-305. PubMed ID: 16857805
[TBL] [Abstract][Full Text] [Related]
11. In vivo depletion of CD4+FOXP3+ Treg cells by the PC61 anti-CD25 monoclonal antibody is mediated by FcgammaRIII+ phagocytes.
Setiady YY; Coccia JA; Park PU
Eur J Immunol; 2010 Mar; 40(3):780-6. PubMed ID: 20039297
[TBL] [Abstract][Full Text] [Related]
12. Increased CD4+CD25+Foxp3+ regulatory T cells in tolerance induced by portal venous injection.
He F; Chen Z; Xu S; Cai M; Wu M; Li H; Chen X
Surgery; 2009 Jun; 145(6):663-74. PubMed ID: 19486771
[TBL] [Abstract][Full Text] [Related]
13. CD25+ regulatory T cell inhibition enhances vaccine-induced immunity to neuroblastoma.
Johnson BD; Jing W; Orentas RJ
J Immunother; 2007; 30(2):203-14. PubMed ID: 17471167
[TBL] [Abstract][Full Text] [Related]
14. Combination of CTL-associated antigen-4 blockade and depletion of CD25 regulatory T cells enhance tumour immunity of dendritic cell-based vaccine in a mouse model of colon cancer.
Saha A; Chatterjee SK
Scand J Immunol; 2010 Feb; 71(2):70-82. PubMed ID: 20384858
[TBL] [Abstract][Full Text] [Related]
15. Targeting CD4+CD25+FoxP3+ regulatory T-cells for the augmentation of cancer immunotherapy.
Schabowsky RH; Madireddi S; Sharma R; Yolcu ES; Shirwan H
Curr Opin Investig Drugs; 2007 Dec; 8(12):1002-8. PubMed ID: 18058571
[TBL] [Abstract][Full Text] [Related]
16. Role of tumor endothelium in CD4+ CD25+ regulatory T cell infiltration of human pancreatic carcinoma.
Nummer D; Suri-Payer E; Schmitz-Winnenthal H; Bonertz A; Galindo L; Antolovich D; Koch M; Büchler M; Weitz J; Schirrmacher V; Beckhove P
J Natl Cancer Inst; 2007 Aug; 99(15):1188-99. PubMed ID: 17652277
[TBL] [Abstract][Full Text] [Related]
17. Two distinct mechanisms of augmented antitumor activity by modulation of immunostimulatory/inhibitory signals.
Mitsui J; Nishikawa H; Muraoka D; Wang L; Noguchi T; Sato E; Kondo S; Allison JP; Sakaguchi S; Old LJ; Kato T; Shiku H
Clin Cancer Res; 2010 May; 16(10):2781-91. PubMed ID: 20460483
[TBL] [Abstract][Full Text] [Related]
18. CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative.
Ghiringhelli F; Larmonier N; Schmitt E; Parcellier A; Cathelin D; Garrido C; Chauffert B; Solary E; Bonnotte B; Martin F
Eur J Immunol; 2004 Feb; 34(2):336-44. PubMed ID: 14768038
[TBL] [Abstract][Full Text] [Related]
19. TGF-beta1 modulates Foxp3 expression and regulatory activity in distinct CD4+ T cell subsets.
Pyzik M; Piccirillo CA
J Leukoc Biol; 2007 Aug; 82(2):335-46. PubMed ID: 17475784
[TBL] [Abstract][Full Text] [Related]
20. Partial depletion of CD69low-expressing natural regulatory T cells with the anti-CD25 monoclonal antibody PC61.
McNeill A; Spittle E; Bäckström BT
Scand J Immunol; 2007 Jan; 65(1):63-9. PubMed ID: 17212768
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]